Prosecution Insights
Last updated: May 29, 2026
Application No. 18/077,276

COMPOSITION FOR FORMING PHOTOCURABLE SILICON-CONTAINING COATING FILM

Final Rejection §102§112
Filed
Dec 08, 2022
Priority
Dec 20, 2017 — JP 2017-244357 +2 more
Examiner
ZIMMER, MARC S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Nissan Chemical Corporation
OA Round
2 (Final)
79%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allowance Rate
1233 granted / 1554 resolved
+14.3% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
37 currently pending
Career history
1600
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
55.7%
+15.7% vs TC avg
§102
13.9%
-26.1% vs TC avg
§112
19.2%
-20.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1554 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . As an initial matter, the Examiner had reached out to Applicants’ representative to see if a small modification of claims 9, 11, and 12- namely to replace each instance of “adjacent patterns” to “adjacent pattern features”- could be negotiated. However, it was subsequently realized that, whereas the claim amendments to claims 8 and 10 had overcome the rejections formulated over Nakajima and Shibayama , the same could not be said of Takei as explained below. The Examiner sincerely regrets any inconvenience to Applicant. Claim Objections Applicant has expounded on the meaning of ISO, DENSE, and “open area” to address misgivings with claims 9, 11, and 12 raised in the previous Office communication. However, the Examiner perceives that the spacing is not that between patterns, or patterned regions, but the spacing between pattern features within said regions. The Examiner will, once more, recommend the aforementioned amendment to resolve this matter. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 8 and 9 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The Examiner perceives that the irradiation conditions attached to the formation of the resist film are actually only disclosed in association with the underlayer film in the original disclosure. It is possible that the resist film-forming composition was subject to same cure conditions but no subject matter was observed that would verify that intent. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 8 and 10 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Takei et al., WO 2007/066597 for the reasons outlined previously and in view of the following considerations: It is simply untrue that Takei teaches baking the photoresist underlayer. Indeed, it is indicated in the title that the underlayer is photocrosslinked. Further, overlapping irradiation wavelengths and dosages- the latter are actually encompassed within the claimed range- are contemplated at the bottom of page 8 of the translated document. Example 1 recites the irradiation of the underlayer film-forming composition at 248 nm and 450 mJ/cm2. Thus, claims 8 and 10 continue to be unpatentable over this particular disclosure. Allowable Subject Matter Claims 11 and 12 are allowable pending successful resolution of the claim objection. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. April 28, 2026 /MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Dec 08, 2022
Application Filed
Dec 19, 2025
Non-Final Rejection mailed — §102, §112
Mar 09, 2026
Response Filed
Apr 30, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12624209
Curable Composition, Reaction Product Therefrom, and Electronic Article Including the Same
3y 5m to grant Granted May 12, 2026
Patent 12624248
CURABLE FORMULATIONS FOR FORMING LOW-k DIELECTRIC SILICON-CONTAINING FILMS USING POLYCARBOSILAZANE
3y 6m to grant Granted May 12, 2026
Patent 12624264
SOLVENTLESS PRESSURE SENSITIVE ADHESIVE COMPOSITION
3y 0m to grant Granted May 12, 2026
Patent 12624056
NOVEL ORGANIC TITANIUM COMPOUND AND CURING CATALYST
2y 10m to grant Granted May 12, 2026
Patent 12624168
METHODS FOR MAKING POLYFUNCTIONAL ORGANOSILOXANES AND COMPOSITIONS CONTAINING SAME
2y 8m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.9%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1554 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month